RxDoctor Payments Data

Jana Davis, PA

Physician Assistant · Rockwall, TXNPI 1932424397

Payments from drug & device makers

$9,760in general payments, 2019–2025

Across 616 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$743
  • Lilly USA, LLC$701
  • Baxter Healthcare$693
  • Amgen$570
  • Pfizer$566
  • plus $5K from 53 others

What the payments were for

  • Food & beverage$8,96792%
  • Education$1001%
  • Other$6937%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie151$1,232
Novo Nordisk48$743
Lilly USA, LLC62$701
Baxter Healthcare1$693
Amgen36$570
Pfizer32$566
Axsome Therapeutics, Inc.15$399
GSK22$368
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC21$337
Corcept Therapeutics7$324
Bayer11$295
Boehringer Ingelheim17$277
AstraZeneca15$257
Astellas Pharma US Inc9$253
Sumitomo Pharma America, Inc.18$244
Kowa Pharmaceuticals America, Inc.13$234
Otsuka America Pharmaceutical, Inc.9$189
Tris Pharma Inc7$152
Merck9$145
Antares Pharma, Inc.8$128
Biohaven Pharmaceuticals, Inc.11$116
Sunovion Pharmaceuticals Inc.10$109
Johnson & Johnson6$96
Corium, LLC3$85
Sanofi-aventis U.S. LLC5$83
Takeda Pharmaceuticals U.S.A., Inc.4$73
Halozyme Inc5$73
Idorsia Pharmaceuticals US Inc4$66
Optinose US, Inc.3$62
Phathom Pharmaceuticals, Inc.6$59
Teva Pharmaceuticals USA, Inc.3$54
Nabriva Therapeutics, PLC3$51
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$48
Eisai Inc.3$45
Almatica Pharma LLC3$44
Shield Therapeutics Inc2$41
Biohaven Pharmaceutical Holding Company Ltd.3$41
Medtronic2$36
Noven Therapeutics, LLC2$36
Amarin Pharma, Inc.2$35
Tonix Medicines, Inc.2$35
Sanofi Pasteur Inc.2$35
Arbor Pharmaceuticals, Inc.2$31
Abbott1$25
Novartis2$24
Dynavax Technologies Corporation1$23
Althera Pharmaceuticals LLC1$21
Ironwood Pharmaceuticals, Inc1$21
Edwards Lifesciences1$20
Exact Sciences1$20
Supernus Pharmaceuticals, Inc.1$20
Collegium Pharmaceutical, Inc.1$20
Tersera Therapeutics LLC1$19
Vanda Pharmaceuticals Inc.1$17
Currax Pharmaceuticals LLC1$16
Jazz Pharmaceuticals Inc.1$15
Adlon Therapeutics L.p.1$15
Dexcom, Inc.1$13
Genentech USA, Inc.1$10

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,760 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$29,443
Medicare patients
131
Services billed
373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$95,738
MounjaroTirzepatide56$64,036
JardianceEmpagliflozin55$59,076
TrulicityDulaglutide41$53,171
EliquisApixaban37$40,298
FarxigaDapagliflozin Propanediol25$30,167
GemtesaVibegron27$23,758
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$21,115
XareltoRivaroxaban18$14,423
SynjardyEmpagliflozin/Metformin Hcl18$12,563
Repatha SureclickEvolocumab11$10,451
LinzessLinaclotide12$9,634
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$5,141
Gabapentin125$2,163
SynthroidLevothyroxine Sodium28$2,150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$701$117,20797 claims
Novo NordiskOzempic$743$95,73872 claims
Boehringer IngelheimJardiance, Synjardy$277$71,63973 claims
PfizerEliquis$566$40,29837 claims
AstraZenecaFarxiga$257$30,16725 claims
Sumitomo Pharma America, Inc.Gemtesa$244$23,75827 claims
GSKTrelegy Ellipta$368$21,11520 claims
Johnson & JohnsonXarelto$96$14,42318 claims
AbbVieLinzess, Synthroid$1,232$11,78440 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Rockwall

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →